<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Clin J Gastroenterol</journal-id><journal-title-group><journal-title>Clinical Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1865-7257</issn><issn pub-type="epub">1865-7265</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39616585</article-id><article-id pub-id-type="pmc">PMC11785699</article-id>
<article-id pub-id-type="publisher-id">2062</article-id><article-id pub-id-type="doi">10.1007/s12328-024-02062-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9862-7861</contrib-id><name><surname>Nagashima</surname><given-names>Shuhei</given-names></name><address><email>shuhei.nagashima@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsunoda</surname><given-names>Shotaro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yamachika</surname><given-names>Yui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tozuka</surname><given-names>Yuichiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fukushima</surname><given-names>Taito</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Morimoto</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ueno</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Furuse</surname><given-names>Junji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maeda</surname><given-names>Shin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00aapa202</institution-id><institution-id institution-id-type="ISNI">0000 0004 0629 2905</institution-id><institution>Department of Gastroenterology, </institution><institution>Kanagawa Cancer Center, </institution></institution-wrap>2-3-2 Nakao Asahi-ku, Yokohama, 241-8515 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0135d1r83</institution-id><institution-id institution-id-type="GRID">grid.268441.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 1033 6139</institution-id><institution>Department of Gastroenterology, </institution><institution>Yokohama City University Graduate School of Medicine, </institution></institution-wrap>3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004 Japan </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>18</volume><issue>1</issue><fpage>125</fpage><lpage>129</lpage><history><date date-type="received"><day>31</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>7</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Cabozantinib is a multi-kinase inhibitor targeting multiple tyrosine kinases. It improves overall survival and progression-free survival in patients previously treated with sorafenib for advanced hepatocellular carcinoma (HCC) compared to the placebo in the phase 3 CELESTIAL trial. A 71-year-old man presented to our hospital for treatment of HCC with chronic hepatitis C. He was refractory to sorafenib, lenvatinib, regorafenib, and ramucirumab and started atezolizumab and bevacizumab therapy in November 2020. After administering the second cycle on December 10, 2020, the patient was diagnosed with progressive disease in January 2021. Therefore, cabozantinib (60 mg/day) was initiated on January 14, 2021. As the grade 3 aspartate aminotransferase and alanine aminotransferase levels increased, grade 3 anorexia and a decline in performance status were observed in the first week, and cabozantinib was terminated. His performance status and anorexia gradually improved, and contrast-enhanced computed tomography (CT) in June 2021 showed complete remission (CR) according to the modified Response Evaluation Criteria in Solid Tumors. The patient did not show disease progression for 11 months without receiving any treatment for HCC. To the best of our knowledge, this is the first report of CR with cabozantinib in advanced HCC.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cabozantinib</kwd><kwd>Hepatocellular carcinoma</kwd><kwd>Immune checkpoint inhibitor</kwd><kwd>Complete remission</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japanese Society of Gastroenterology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths [<xref ref-type="bibr" rid="CR1">1</xref>]. For patients with early-stage HCC, treatment options include surgical resection, liver transplantation, radiation therapy, and ablation [<xref ref-type="bibr" rid="CR2">2</xref>]. However, HCC is often inoperable owing to a late diagnosis, and systemic chemotherapy may be the only treatment option for such patients. Immune checkpoint inhibitors have significantly changed the treatment of HCC in recent years; atezolizumab plus bevacizumab and durvalumab plus tremelimumab improve overall survival compared with sorafenib [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Other treatment options include sorafenib, lenvatinib, regorafenib, ramucirumab, and cabozantinib.</p><p id="Par3">Cabozantinib is a multi-kinase inhibitor that targets multiple tyrosine kinases. The phase 3 CELESTIAL trial showed improved efficacy outcomes compared to the placebo in previously sorafenib-treated patients with advanced HCC [<xref ref-type="bibr" rid="CR5">5</xref>]. However, there are no reports of complete remission (CR) following cabozantinib monotherapy. Here, we report a case of CR according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) using cabozantinib as an end-line therapy for advanced HCC.</p></sec><sec id="Sec2"><title>Case report</title><p id="Par4">A 71-year-old man received interferon therapy for hepatitis C in 2009. Despite the sustained virological response to hepatitis C, HCC developed in S2 and S3 in December 2016, and lateral segmentectomy was performed. In October 2017, lymph node metastases were identified near the hepatic hilum, hepatoduodenal ligament, and peritoneal dissemination node and recurrence were diagnosed. In November 2017, disseminated lesion resection and cholecystectomy were performed, and the patient was referred to another hospital for subsequent treatment. In December 2017, contrast-enhanced computed tomography (CT) revealed that there were still many peritoneal nodules. Sorafenib was started in January 2018, followed by lenvatinib, regorafenib, and ramucirumab. However, the patient did not respond to the treatment, and liver metastasis and peritoneal dissemination were aggravated in August 2020. The patient visited our hospital for further treatment of HCC in September 2020.</p><p id="Par5">Contrast-enhanced CT revealed an HCC with a maximum diameter of 10 cm centered on hepatic segments 5 and 8, with a peritoneal dissemination nodule measuring 22 mm in maximum diameter near the hepatoduodenal ligament and a maximum diameter of 35 mm near the omentum (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Minimal ascites was observed on the liver surface, raising suspicion of peritoneal dissemination. On admission, the patient was Child&#x02013;Pugh class A, with a score of 5. First, we performed transcatheter arterial chemoembolization (TACE) on the intrahepatic lesions to control the tumor and prevent bleeding owing to tumor rupture. Post-treatment CT showed attenuation of enhancement in the intrahepatic lesions; however, intrahepatic lesions and peritoneal dissemination progressed (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Therefore, we initiated atezolizumab and bevacizumab therapy on November, 2020. There were no obvious treatment-related adverse events; however, progression of all lesions was observed on contrast-enhanced CT after the administration of the second course of atezolizumab and bevacizumab on December, 2020 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) levels temporarily decreased but increased again after two courses of administration. Based on these findings, we diagnosed the patient with progressive disease (PD) and terminated atezolizumab and bevacizumab therapy. Subsequently, cabozantinib treatment (60 mg orally once daily) was initiated on January, 2021. Although liver enzymes were not elevated before the initiation of cabozantinib therapy, grade 3 increases in aspartate aminotransferase and alanine aminotransferase levels (386&#x000a0;IU/L and 105&#x000a0;IU/L, respectively) and anorexia, and grade 1 nausea and vomiting (according to the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) were observed 1 week after the start of cabozantinib treatment (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Contrast-enhanced CT showed attenuation of enhancement in the liver lesion and peritoneal dissemination (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c), and tumor markers (including AFP and DCP) decreased (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). However, the decrease in performance status was significant even after treatment interruption, and patients with grade 3 anorexia did not recover. Therefore, we thought that these symptoms resulted from disease progression, and he received only the best supportive care thereafter. His physical condition and activities of daily living had worsened, making it difficult for him to visit the hospital. Finally, the patient and his family opted for home care.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Contrast-enhanced computed tomography upon admission to our hospital</p></caption><graphic xlink:href="12328_2024_2062_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Changes in contrast-enhanced computed tomography image after treatment in our hospital</p></caption><graphic xlink:href="12328_2024_2062_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Laboratory findings after cabozantinib administration</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Day 1</th><th align="left">Day 8</th><th align="left">Day 15</th><th align="left">Day 19</th><th align="left">Day 26</th><th align="left">Day 140</th></tr></thead><tbody><tr><td align="left">Alb (g/dL)</td><td align="left">3.6</td><td align="left">3.4</td><td align="left">3.1</td><td align="left">3.2</td><td align="left">3.2</td><td align="left">4.1</td></tr><tr><td align="left">T-Bil (mg/dL)</td><td align="left">0.8</td><td align="left">0.8</td><td align="left">0.9</td><td align="left">0.9</td><td align="left">1.2</td><td align="left">0.4</td></tr><tr><td align="left">LDH (U/L)</td><td align="left">367</td><td align="left">1221</td><td align="left">862</td><td align="left">810</td><td align="left">506</td><td align="left">183</td></tr><tr><td align="left">AST (U/L)</td><td align="left">49</td><td align="left">386</td><td align="left">238</td><td align="left">186</td><td align="left">82</td><td align="left">19</td></tr><tr><td align="left">ALT (U/L)</td><td align="left">21</td><td align="left">65</td><td align="left">65</td><td align="left">55</td><td align="left">34</td><td align="left">9</td></tr><tr><td align="left">ALP (U/L)</td><td align="left">560</td><td align="left">647</td><td align="left">563</td><td align="left">565</td><td align="left">467</td><td align="left">330</td></tr><tr><td align="left">&#x003b3;-GTP (U/L)</td><td align="left">129</td><td align="left">142</td><td align="left">108</td><td align="left">96</td><td align="left">73</td><td align="left">44</td></tr><tr><td align="left">CRP (mg/dL)</td><td align="left">2.58</td><td align="left">10.94</td><td align="left">7.52</td><td align="left">4.71</td><td align="left">3.14</td><td align="left">0.12</td></tr><tr><td align="left">WBC (/&#x000b5;L)</td><td align="left">5600</td><td align="left">6200</td><td align="left">5700</td><td align="left">6100</td><td align="left">3100</td><td align="left">6100</td></tr></tbody></table><table-wrap-foot><p><italic>Cr</italic> creatinine, <italic>CRP</italic> carbohydrate reaction protein</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Tumor markers upon admission to our hospital</p></caption><graphic xlink:href="12328_2024_2062_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Tumor markers from admission to follow-up after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Months from initial treatment</th><th align="left">0</th><th align="left">1</th><th align="left">2</th><th align="left">3</th><th align="left">4</th><th align="left">5</th><th align="left">9</th></tr></thead><tbody><tr><td align="left">AFP (ng/mL)</td><td align="left">20,179.8</td><td align="left">24,796</td><td align="left">10,075</td><td align="left">30,512</td><td align="left">44,318.8</td><td align="left">17,132.3</td><td align="left">9.2</td></tr><tr><td align="left">DCP (mAU/mL)</td><td align="left">5780</td><td align="left">7590</td><td align="left">1690</td><td align="left">22,100</td><td align="left">34,700</td><td align="left">5440</td><td align="left">22</td></tr></tbody></table></table-wrap></p><p id="Par6">Along with continued supportive care at home, the symptoms of anorexia and oral intake gradually improved, as did his physical condition. He visited our hospital in June 2021. Contrast-enhanced CT showed attenuation of blood flow in the intrahepatic lesion and peritoneal dissemination nodules, and the tumor size decreased, leading to a diagnosis of CR according to mRECIST (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). The tumors did not progress until April 2022 without any treatment for HCC; however, partial recurrence with increased blood flow on contrast-enhanced CT was observed under the hepatic capsule, leading to a diagnosis of hepatic local recurrence. As there was no obvious recurrence, except for this lesion, carbon-iron radiotherapy (60 GyE/12 fractions) was initiated from June 2022. He has been free from tumor progression and was reported alive until November 2023 (34&#x000a0;months after CR).</p></sec><sec id="Sec3"><title>Discussion</title><p id="Par7">We encountered a patient with advanced HCC who showed a CR with cabozantinib following the sixth treatment immediately after treatment with atezolizumab plus bevacizumab. This is the first study reporting a CR with cabozantinib in advanced HCC.</p><p id="Par8">There are two possible reasons for the remarkable effects of cabozantinib observed in this case. One reason might be genetic alterations. Cabozantinib is a tyrosine kinase inhibitor (TKI) that targets receptor kinases involved in immune regulation, tumor growth, and angiogenesis. Its targets include receptor kinases of the VEGFR, MET, and TAM (TYRO3, AXL, and MER) families [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Several case reports have reported the remarkable effectiveness of cabozantinib when C-MET gene amplification was observed [<xref ref-type="bibr" rid="CR8">8</xref>]. Unfortunately, we did not perform a liver biopsy or obtain specimens from recurrent tumors; therefore, genetic testing was not performed in this case. Liver tumor biopsy is not mandatory for diagnosing HCC, and aggressive surgery is often avoided owing to complications such as bleeding, dissemination, and decompensation of the liver function reserve. However, evaluating gene alterations using next-generation sequencing (NGS) can help predict the efficacy of cabozantinib, and tissue sampling and NGS may be encouraged for advanced HCC in the future [<xref ref-type="bibr" rid="CR8">8</xref>]. The second reason may be that cabozantinib has immunomodulatory activity. HCC is also associated with immune tolerance [<xref ref-type="bibr" rid="CR9">9</xref>]. This may be linked to the overexpression of cytokine pathways in the tumor microenvironment. Overexpression of cytokine pathways may result in the inhibition of cells associated with the immune response and recruitment of immunosuppressive cells [<xref ref-type="bibr" rid="CR10">10</xref>]. VEGF overexpression is frequently observed in HCC. Inhibition of T cell function and dendritic cell differentiation, and increased regulatory T cells and myeloid-derived suppressor cells can limit antitumor immune responses [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Thus, combining immune checkpoint inhibitors with VEGF-pathway inhibitors and other immunomodulatory pathways may promote an immune-tolerant environment and enhance immune checkpoint inhibitor responses. Moreover, combining cabozantinib and atezolizumab shows efficacy compared to sorafenib monotherapy in the COSMIC-312 trial, and one patient achieved CR [<xref ref-type="bibr" rid="CR12">12</xref>]. In the CheckMate 9ER trial, the combination of cabozantinib and nivolumab showed better efficacy in renal cell carcinoma than sunitinib alone [<xref ref-type="bibr" rid="CR13">13</xref>]. These results indicate the efficacy of combination therapy with cabozantinib and an immune checkpoint inhibitor. The efficacy and safety of cabozantinib in patients previously treated with ICI-based therapy have been confirmed in various studies [<xref ref-type="bibr" rid="CR14">14</xref>]. Although cabozantinib was not concurrently used with atezolizumab in the current case, the effect of atezolizumab may have persisted at the time of cabozantinib initiation since nivolumab binds to T cells over 20 weeks after administration [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par9">The possibility of pseudo-progression showing a temporary increase in tumor size owing to immune cell infiltration and a temporary decrease in PS linked to immune-related adverse events should be excluded [<xref ref-type="bibr" rid="CR16">16</xref>]. In this case, we diagnosed &#x0201c;true&#x0201d; progression against atezolizumab plus bevacizumab since the radiological and laboratory findings indicated disease progression after two courses of treatment.</p><p id="Par10">The present case demonstrated CR according to the mRECIST assessment, and attention should be paid to the fact that the RESIST assessment is a partial response. Although the tumor has shrunken over time, partial recurrence was observed, which required careful follow-up.</p><p id="Par11">Herein, we report a case of advanced HCC that showed a CR with cabozantinib. We hope that more case reports in the future will help elucidate patients that can achieve CR with cabozantinib.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank HONYAKU CENTER INC. (<ext-link ext-link-type="uri" xlink:href="https://www.honyakuctr.com">https://www.honyakuctr.com</ext-link>) for the English language review.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All the authors contributed to the study conception and design. Data collection and analysis were performed by Shuhei Nagashima and Satoshi Kobayashi. The first draft of the manuscript was written by Shuhei Nagashima and reviewed by all the authors. All the authors read and approved the final version of the manuscript.</p></notes><notes><title>Declarations</title><notes><title>Informed consent</title><p id="Par12">This study does not involve human participants; therefore, the requirement for informed consent was waived.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2021</year><volume>7</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00240-3</pub-id><pub-id pub-id-type="pmid">33479224</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.<pub-id pub-id-type="pmid">33479224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Grandhi</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>AK</given-names></name><name><surname>Ronnekleiv-Kelly</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma: from diagnosis to treatment</article-title><source>Surg Oncol</source><year>2016</year><volume>25</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.suronc.2016.03.002</pub-id><pub-id pub-id-type="pmid">27312032</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25:74&#x02013;85.<pub-id pub-id-type="pmid">27312032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1894</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1915745</pub-id><pub-id pub-id-type="pmid">32402160</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894&#x02013;905.<pub-id pub-id-type="pmid">32402160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Lau</surname><given-names>G</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma</article-title><source>N Engl J Med Evid</source><year>2022</year><volume>1</volume><issue>8</issue><fpage>EVIDoa2100070</fpage></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Abou-Alfa GK, Lau G, Kudo M, Pharm MM, He P, Kurland JF, Negro A, Sangro B, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. N Engl J Med Evid. 2022;1(8): EVIDoa2100070.</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Cabozantinib in patients with advanced and progressing hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1717002</pub-id><pub-id pub-id-type="pmid">29972759</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54&#x02013;63.<pub-id pub-id-type="pmid">29972759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Bergerot</surname><given-names>P</given-names></name><name><surname>Lamb</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence</article-title><source>Mol Cancer Ther</source><year>2019</year><volume>18</volume><fpage>2185</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-1399</pub-id><pub-id pub-id-type="pmid">31792125</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bergerot P, Lamb P, Wang E, et al. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18:2185&#x02013;93.<pub-id pub-id-type="pmid">31792125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Yakes</surname><given-names>FM</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</article-title><source>Mol Cancer Ther</source><year>2011</year><volume>10</volume><fpage>2298</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0264</pub-id><pub-id pub-id-type="pmid">21926191</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298&#x02013;308.<pub-id pub-id-type="pmid">21926191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>YB</given-names></name><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dramatic response to cabozantinib in a patient with refractory hepatocellular carcinoma with c-MET amplification</article-title><source>J Clin Transl Hepatol</source><year>2023</year><volume>11</volume><fpage>747</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">36969903</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sang YB, Kim G, Hwang S, et al. Dramatic response to cabozantinib in a patient with refractory hepatocellular carcinoma with c-MET amplification. J Clin Transl Hepatol. 2023;11:747&#x02013;50.<pub-id pub-id-type="pmid">36969903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Shlomai</surname><given-names>A</given-names></name><name><surname>de Jong</surname><given-names>YP</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group><article-title>Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma</article-title><source>Semin Cancer Biol</source><year>2014</year><volume>26</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2014.01.004</pub-id><pub-id pub-id-type="pmid">24457013</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78&#x02013;88.<pub-id pub-id-type="pmid">24457013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Targeting VEGF/VEGFR to modulate antitumor immunity</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>978</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00978</pub-id><pub-id pub-id-type="pmid">29774034</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.<pub-id pub-id-type="pmid">29774034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><etal/></person-group><article-title>From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><fpage>396</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1396-4</pub-id><pub-id pub-id-type="pmid">31500650</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Fu Y, Liu S, Zeng S, et al. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:396.<pub-id pub-id-type="pmid">31500650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Rimassa</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><fpage>995</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00326-6</pub-id><pub-id pub-id-type="pmid">35798016</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995&#x02013;1008.<pub-id pub-id-type="pmid">35798016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Burotto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><fpage>888</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00290-X</pub-id><pub-id pub-id-type="pmid">35688173</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888&#x02013;98.<pub-id pub-id-type="pmid">35688173</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Multiventre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment</article-title><source>J Hepatol</source><year>2024</year><volume>81</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2024.03.033</pub-id><pub-id pub-id-type="pmid">38570034</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Chan SL, Ryoo BY, Mo F, et al. Multiventre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024;81:258&#x02013;64.<pub-id pub-id-type="pmid">38570034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Osa</surname><given-names>A</given-names></name><name><surname>Uenami</surname><given-names>T</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><issue>19</issue><fpage>e59125</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.59125</pub-id><pub-id pub-id-type="pmid">30282824</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3(19): e59125.<pub-id pub-id-type="pmid">30282824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>VL</given-names></name><name><surname>Burotto</surname><given-names>M</given-names></name></person-group><article-title>Pseudoprogression and immune-related response in solid tumors</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>3541</fpage><lpage>3543</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.61.6870</pub-id><pub-id pub-id-type="pmid">26261262</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541&#x02013;3.<pub-id pub-id-type="pmid">26261262</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>